Ann M. Leen - Jan 18, 2022 Form 4 Insider Report for Allovir, Inc. (ALVR)

Role
Chief Scientific Officer
Signature
/s/ Brett Hagen, as Attorney-in-Fact
Stock symbol
ALVR
Transactions as of
Jan 18, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2023, 04:00 PM
Previous filing
Nov 16, 2021
Next filing
Aug 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALVR Common Stock Award $0 +23.3K +83.06% $0.00 51.3K Jan 18, 2022 Direct F1
transaction ALVR Common Stock Award $0 +14K +27.31% $0.00 65.3K Jul 1, 2022 Direct F2
transaction ALVR Common Stock Award $0 +43.8K +54.51% $0.00 124K Feb 2, 2023 Direct F3
holding ALVR Common Stock 2.29M Jan 18, 2022 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALVR Stock Option (Right to Buy) Award $0 +56.7K +18.33% $0.00 366K Jan 18, 2022 Common Stock 56.7K $9.15 Direct F5
transaction ALVR Stock Option (Right to Buy) Award $0 +26K +7.1% $0.00 392K Jul 1, 2022 Common Stock 26K $4.13 Direct F6
transaction ALVR Stock Option (Right to Buy) Award $0 +81.3K +20.71% $0.00 474K Feb 2, 2023 Common Stock 81.3K $6.65 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F2 The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F3 The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.
F4 Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F5 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F6 25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F7 25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.